Lipid Management Guidelines

Primary Targets and Risk Stratification

The European Society of Cardiology recommends risk-stratified LDL cholesterol targets, with very high-risk patients requiring LDL-C <70 mg/dL or at least 50% reduction from baseline, and high-risk patients targeting LDL-C <100 mg/dL or at least 50% reduction 1, 2
Very high-risk patients, including those with documented cardiovascular disease, diabetes mellitus, or moderate-to-severe chronic kidney disease, should target LDL-C <70 mg/dL (1.8 mmol/L) or achieve a ≥50% reduction from baseline 1, 2
High-risk patients should target LDL-C <100 mg/dL (2.6 mmol/L) or achieve a ≥50% reduction from baseline 1, 2
The American Heart Association and American College of Cardiology emphasize LDL-C as the cornerstone of lipid management, with a focus on percentage reductions and statin intensity 3, 4

Statins are the first-line treatment to reach LDL-C goals, with high-dose statins recommended for acute coronary syndrome patients regardless of initial LDL-C values 1, 2
The European Society of Cardiology recommends achieving at least a 30-40% reduction in LDL-C levels when using LDL-lowering drug therapy in high or moderately high-risk persons 5
Combination therapy with a fibrate or nicotinic acid may be considered for high-risk patients with elevated triglycerides or low HDL-C 5

Non-HDL cholesterol may be a better predictor of cardiovascular risk than LDL alone, especially in patients with elevated triglycerides, and is recommended as a secondary target in certain patient groups 6
Treatment with statins is recommended for older adults with established cardiovascular disease, similar to younger patients 1, 2
Familial hypercholesterolemia should be suspected in adults with LDL-C >190 mg/dL or children with LDL-C >150 mg/dL, or those with coronary heart disease before age 55 in men or 60 in women 1, 2

The European Society of Cardiology and European Atherosclerosis Society guidelines are more aggressive with specific absolute LDL-C targets, while the American Heart Association and American College of Cardiology guidelines focus on percentage reductions and are more conservative regarding non-statin therapies 3, 4
The 2013 American Heart Association and American College of Cardiology guidelines removed specific treatment targets, but the European Society of Cardiology and European Atherosclerosis Society guidelines continue to endorse "treat-to-target" strategies 7

The American College of Cardiology states that LDL is the dominant atherogenic lipoprotein that promotes atherosclerosis, while HDL is protective against atherosclerotic cardiovascular disease (ASCVD) 8, 9
LDL transports cholesterol to peripheral tissues and can deposit in arterial walls, promoting plaque formation, as noted by the American College of Cardiology 8

The American College of Cardiology recommends the following LDL cholesterol categories: Very high (≥175 mg/dL), High (150-174 mg/dL), Borderline high (125-149 mg/dL), Borderline low (100-124 mg/dL), Low (75-99 mg/dL), Very low (50-74 mg/dL), and Optimal (<100 mg/dL) 8, 10, 11
The European Heart Journal suggests the following HDL cholesterol targets: Low (increased risk, <40 mg/dL in men, <45 mg/dL in women), Desirable (40-59 mg/dL), and Optimal (protective, ≥60 mg/dL) 11, 12

The American College of Cardiology establishes LDL as the primary target of cholesterol-lowering therapy in most guidelines, with the relationship between LDL reduction and cardiovascular risk following "the lower, the better" principle 8, 13
Non-HDL cholesterol (total cholesterol minus HDL) may be a better predictor of ASCVD risk than LDL alone, especially in patients with elevated triglycerides, according to the American College of Cardiology and the European Heart Journal 8, 14
The ratio of total cholesterol to HDL or LDL to HDL provides additional risk stratification, as noted by the European Heart Journal 14

The American College of Cardiology recommends statins as first-line therapy for LDL reduction, lowering LDL by 35-55% depending on type and dose, and other LDL-lowering options include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors 8, 10
The European Heart Journal notes that while low HDL is an established risk factor, pharmacologic HDL-raising has not consistently shown outcome benefits 11

The International Lipid Expert Panel (ILEP) recommends aggressive, early LDL-C lowering with the principle "lower is better for longer" and "the earlier the better," targeting LDL-C <70 mg/dL for very high-risk patients and advocating for upfront combination therapy in extremely high-risk individuals to reduce cardiovascular mortality and morbidity, as stated by the 2024 ILEP guidelines 15, 16
Acute coronary syndrome (ACS) patients are considered very high-risk and should be treated according to the 2024 ILEP guidelines 15, 16

The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines are more aggressive with specific absolute LDL-C targets and broader use of combination therapy, while the American Heart Association (AHA) and American College of Cardiology (ACC) guidelines are more conservative, focusing on percentage reductions and incorporating cost-effectiveness considerations, as noted in the Mayo Clinic Proceedings 17, 18
The ESC/EAS approach recommends specific absolute LDL-C concentration targets plus percentage reductions, assumes unlimited resources, and supports liberal use of PCSK9 inhibitors and combination therapy across broader patient groups, as stated in the Mayo Clinic Proceedings 17, 18
The AHA/ACC approach emphasizes percentage reductions with statin intensity, incorporates cost-value considerations, and reserves non-statin additions only for select very high-risk patients with specific LDL-C thresholds, as noted in the Mayo Clinic Proceedings 17, 18

The 2024 ILEP guidelines advocate for upfront combination therapy in extremely high-risk individuals to improve adherence and effectiveness, and bempedoic acid represents an additional effective option for very high and extremely high cardiovascular risk patients 15, 16
If LDL-C targets are not achieved with maximally tolerated statin therapy, add ezetimibe as the next step, followed by PCSK9 inhibitors or inclisiran for persistently elevated LDL-C in very high-risk patients, as recommended by the 2024 ILEP guidelines 15, 16

The European guidelines use SCORE (Systematic COronary Risk Evaluation) based on fatal events only, recently updated to extend age range to 70 years, while the American guidelines use Pooled Cohort Equations (PCE) predicting both fatal and nonfatal ASCVD events, as noted in the Mayo Clinic Proceedings 18
Both recommend 10-year ASCVD risk estimation for primary prevention, as stated in the Mayo Clinic Proceedings 18

Despite available effective therapies, clinical practice goals are not met in up to 70% of patients, representing a major treatment gap that requires systematic approaches to improve access, adherence, and early intensive therapy, as noted in the 2024 ILEP guidelines 15, 16
Delaying combination therapy is a common pitfall to avoid, and the 2024 guidelines emphasize early aggressive treatment rather than sequential monotherapy titration in very high-risk patients, as recommended by the 2024 ILEP guidelines 15, 16